Literature DB >> 12915559

The Moloney murine leukemia virus repressor binding site represses expression in murine and human hematopoietic stem cells.

Dennis L Haas1, Carolyn Lutzko, Aaron C Logan, Gerald J Cho, Dianne Skelton, Xiao Jin Yu, Karen A Pepper, Donald B Kohn.   

Abstract

The Moloney murine leukemia virus (MLV) repressor binding site (RBS) is a major determinant of restricted expression of MLV in undifferentiated mouse embryonic stem (ES) cells and mouse embryonal carcinoma (EC) lines. We show here that the RBS repressed expression when placed outside of its normal MLV genome context in a self-inactivating (SIN) lentiviral vector. In the lentiviral vector genome context, the RBS repressed expression of a modified MLV long terminal repeat (MNDU3) promoter, a simian virus 40 promoter, and three cellular promoters: ubiquitin C, mPGK, and hEF-1a. In addition to repressing expression in undifferentiated ES and EC cell lines, we show that the RBS substantially repressed expression in primary mouse embryonic fibroblasts, primary mouse bone marrow stromal cells, whole mouse bone marrow and its differentiated progeny after bone marrow transplant, and several mouse hematopoietic cell lines. Using an electrophoretic mobility shift assay, we show that binding factor A, the trans-acting factor proposed to convey repression by its interaction with the RBS, is present in the nuclear extracts of all mouse cells we analyzed where expression was repressed by the RBS. In addition, we show that the RBS partially repressed expression in the human hematopoietic cell line DU.528 and primary human CD34(+) CD38(-) hematopoietic cells isolated from umbilical cord blood. These findings suggest that retroviral vectors carrying the RBS are subjected to high rates of repression in murine and human cells and that MLV vectors with primer binding site substitutions that remove the RBS may yield more-effective gene expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915559      PMCID: PMC187403          DOI: 10.1128/jvi.77.17.9439-9450.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Determinants of retrovirus gene expression in embryonal carcinoma cells.

Authors:  E Akgün; M Ziegler; M Grez
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

2.  Retrovirus-mediated insertion of expressed and non-expressed genes at identical chromosomal locations.

Authors:  B Berwin; E Barklis
Journal:  Nucleic Acids Res       Date:  1993-05-25       Impact factor: 16.971

3.  Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells.

Authors:  M Grez; E Akgün; F Hilberg; W Ostertag
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

4.  Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors.

Authors:  D L Haas; S S Case; G M Crooks; D B Kohn
Journal:  Mol Ther       Date:  2000-07       Impact factor: 11.454

5.  Stimulatory effects of granulocyte colony-stimulating factor on colony-forming units-spleen (CFU-S) differentiation and pre-CFU-S proliferation in mice.

Authors:  T Tanaka; T Suda; J Suda; T Inoue; Y Hirabayashi; H Hirai; F Takaku; Y Miura
Journal:  Blood       Date:  1991-06-15       Impact factor: 22.113

6.  Derivatives of Moloney murine sarcoma virus capable of being transcribed in embryonal carcinoma stem cells have gained a functional Sp1 binding site.

Authors:  V E Prince; P W Rigby
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

7.  Characterization of the Moloney murine leukemia virus stem cell-specific repressor binding site.

Authors:  G Kempler; B Freitag; B Berwin; O Nanassy; E Barklis
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

8.  A single point mutation activates the Moloney murine leukemia virus long terminal repeat in embryonal stem cells.

Authors:  M Grez; M Zörnig; J Nowock; M Ziegler
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

9.  A stem cell-specific silencer in the primer-binding site of a retrovirus.

Authors:  R Petersen; G Kempler; E Barklis
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

10.  Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector.

Authors:  S Halene; L Wang; R M Cooper; D C Bockstoce; P B Robbins; D B Kohn
Journal:  Blood       Date:  1999-11-15       Impact factor: 25.476

View more
  16 in total

1.  Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells.

Authors:  Mingjie Li; Nada Husic; Ying Lin; Heather Christensen; Ibrahim Malik; Sally McIver; Christine M LaPash Daniels; David A Harris; Paul T Kotzbauer; Mark P Goldberg; B Joy Snider
Journal:  J Neurosci Methods       Date:  2010-03-27       Impact factor: 2.390

Review 2.  Host restriction factors blocking retroviral replication.

Authors:  Daniel Wolf; Stephen P Goff
Journal:  Annu Rev Genet       Date:  2008       Impact factor: 16.830

3.  Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system.

Authors:  Teiko Sumiyoshi; Nathalia G Holt; Roger P Hollis; Shundi Ge; Paula M Cannon; Gay M Crooks; Donald B Kohn
Journal:  Hum Gene Ther       Date:  2009-12       Impact factor: 5.695

4.  Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers.

Authors:  Elizabeth L Siegler; Yu Jeong Kim; Xianhui Chen; Natnaree Siriwon; John Mac; Jennifer A Rohrs; Paul D Bryson; Pin Wang
Journal:  Mol Ther       Date:  2017-08-19       Impact factor: 11.454

5.  Development of lentiviral vectors with regulated respiratory epithelial expression in vivo.

Authors:  Benjamin Hendrickson; Dinithi Senadheera; Suparna Mishra; Kim Chi T Bui; Xingchao Wang; Belinda Chan; Denise Petersen; Karen Pepper; Carolyn Lutzko
Journal:  Am J Respir Cell Mol Biol       Date:  2007-06-15       Impact factor: 6.914

6.  Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.

Authors:  Fabio Candotti; Kit L Shaw; Linda Muul; Denise Carbonaro; Robert Sokolic; Christopher Choi; Shepherd H Schurman; Elizabeth Garabedian; Chimene Kesserwan; G Jayashree Jagadeesh; Pei-Yu Fu; Eric Gschweng; Aaron Cooper; John F Tisdale; Kenneth I Weinberg; Gay M Crooks; Neena Kapoor; Ami Shah; Hisham Abdel-Azim; Xiao-Jin Yu; Monika Smogorzewska; Alan S Wayne; Howard M Rosenblatt; Carla M Davis; Celine Hanson; Radha G Rishi; Xiaoyan Wang; David Gjertson; Otto O Yang; Arumugam Balamurugan; Gerhard Bauer; Joanna A Ireland; Barbara C Engel; Gregory M Podsakoff; Michael S Hershfield; R Michael Blaese; Robertson Parkman; Donald B Kohn
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

7.  Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction.

Authors:  Denise A Carbonaro; Xiangyang Jin; Xingchao Wang; Xiao-Jin Yu; Nora Rozengurt; Michael L Kaufman; Xiaoyan Wang; David Gjertson; Yang Zhou; Michael R Blackburn; Donald B Kohn
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

8.  KAP1 controls endogenous retroviruses in embryonic stem cells.

Authors:  Helen M Rowe; Johan Jakobsson; Daniel Mesnard; Jacques Rougemont; Séverine Reynard; Tugce Aktas; Pierre V Maillard; Hillary Layard-Liesching; Sonia Verp; Julien Marquis; François Spitz; Daniel B Constam; Didier Trono
Journal:  Nature       Date:  2010-01-14       Impact factor: 49.962

9.  Site-specific modulation of brain glucocorticoid receptor and corticotropin-releasing hormone expression using lentiviral vectors.

Authors:  Gloria Laryea; Melinda G Arnett; Lindsay Wieczorek; Louis J Muglia
Journal:  Mol Cell Endocrinol       Date:  2012-12-20       Impact factor: 4.102

10.  TRIM28 mediates primer binding site-targeted silencing of Lys1,2 tRNA-utilizing retroviruses in embryonic cells.

Authors:  Daniel Wolf; Kevin Hug; Stephen P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.